Highlights
NASDAQ: BGNE       Beigene Ltd. Ads
Last Price Today's Change   Day's Range   Trading Volume
93.72   -0.64 (0.68%)  91.05 - 96.55  321,503

Overview

 
Avg Volume (4 weeks):304,055
4 Weeks Range:80.77 - 118.95
4 Weeks Price Volatility (%):
33.92%
52 Weeks Range:26.43 - 118.95
52 Weeks Price Volatility (%):
72.73%
Average Price Target:-

Headlines



No recent Headlines for this stock.


Business Background

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.

  Be the first to like this.
 


 

2885  4298  592  678 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 TRXC 2.81+1.35 
 BAC 26.24+0.41 
 GE 23.36+0.38 
 RAD 1.86+0.12 
 GDX 23.46-0.38 
 VALE 10.50+0.05 
 XLF 26.30+0.17 
 PCG 53.43-4.29 
 SPY 255.29+0.34 
 EEM 46.63-0.03 
Partners & Brokers